S
Simon Maltais
Researcher at Mayo Clinic
Publications - 196
Citations - 4471
Simon Maltais is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Ventricular assist device & Heart failure. The author has an hindex of 32, co-authored 193 publications receiving 3507 citations. Previous affiliations of Simon Maltais include Vanderbilt University & Université de Sherbrooke.
Papers
More filters
Journal ArticleDOI
PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management (PREVENT)
Simon Maltais,Ahmet Kilic,Sriram Nathan,Mary E. Keebler,Sitaramesh Emani,John Ransom,Jason N. Katz,Brett C. Sheridan,Andreas Brieke,G. Egnaczyk,John W. Entwistle,Robert M. Adamson,John M. Stulak,Nir Uriel,John B. O'Connell,D. Farrar,Kartik S. Sundareswaran,Igor D. Gregoric +17 more
Journal ArticleDOI
Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
Rabea Asleh,Alexandros Briasoulis,Naveen L. Pereira,Barry A. Boilson,Brooks S. Edwards,Rosalyn Adigun,Simon Maltais,Richard C. Daly,Amir Lerman,Sudhir S. Kushwaha +9 more
TL;DR: This work sought to investigate the effect of early statin (ES) as compared with late statin initiation after heart transplantation (HT) on long‐term CAV progression and clinical outcomes in a large contemporary HT cohort.
Journal ArticleDOI
Two-Year Follow Up of the LATERAL Clinical Trial: A Focus on Adverse Events.
Georg Wieselthaler,Liviu Klein,Anson Cheung,Matthew R. Danter,Martin Strueber,Claudius Mahr,Nahush A. Mokadam,Simon Maltais,Edwin C. McGee +8 more
TL;DR: The LATERAL trial validated the safety and efficacy of the thoracotomy approach for implantation of the HeartWare HVAD System, leading to Food and Drug Administration approval.
Journal ArticleDOI
Early Gains in Renal Function Following Implantation of HeartMate II Left Ventricular Assist Devices May Not Persist to One Year.
Tal Hasin,Avishay Grupper,John J. Dillon,Joseph J. Maleszewski,Zhuo Li,Yan Topilsky,Robert P. Frantz,Brooks S. Edwards,Naveen L. Pereira,Simon Maltais,John M. Stulak,Lyle D. Joyce,Richard C. Daly,Soon J. Park,Sudhir S. Kushwaha +14 more
TL;DR: Early gains in renal function after LVAD implant are not sustained in many patients, and patient, device, and operative factors may influence long-term renal function in these patients.
Journal ArticleDOI
The neurogenic origin of hypertension in SHR may be mediated by angiotensin II through a receptor different from AT1 and AT2.
TL;DR: In the CNS of the young SHR, an active Renin-Ang-System is implicated in the establishment of the hypertensive state, and that the receptor for this function is different from AT1 and AT2, since it has a selectivity profile different from At1 andAT2 receptor types.